BIAF · bioAffinity Technologies, Inc. · Executive Compensation
$6.06
-0.09 (-1.46%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current expected level of operating expenditures, current expected levels of revenue, and the cash and cash equivalents on hand at June 30, 2026, of $2.4 million, management concludes that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements contained in this Quarterly Report.”View the 10-Q filed Aug 7, 2026
Market Cap
$3.72M
Shares
540,115
Volume · Oct 2
154.64K
Avg daily vol (29 sessions)
6.44M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $434,983 |
| J. Michael Edwards | Chief Financial Officer | $368,455 |
| Michael Edwards | CFO | $368,455 |
| Steven Girgenti | Executive Chairman | $261,860 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $477,155 |
| Steven Girgenti | Executive Chairman | $366,679 |
| J. Michael Edwards | Chief Financial Officer | $273,213 |
| Michael Edwards | CFO | $273,213 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $424,168 |
| Michael Dougherty | Vice President and CFO | $338,919 |
| Steven Girgenti | Executive Chairman | $248,745 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $351,287 |
| Vivienne Rebel | EVP; Chief Science & Medical Officer | $257,566 |
| Steven Girgenti | Executive Chairman | $153,333 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $264,404 |
| Vivienne Rebel | EVP; Chief Science & Medical Officer | $249,790 |
| Steven Girgenti | Executive Chairman | $193,222 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John J. Oppenheimer | member of the Board | Appointed | 2025-08-18 |
| Gary Rubin | Board | Resigned | 2025-08-18 |
| Roberto Rios | member of the Board | Appointed | 2025-08-18 |
| J. Michael Edwards | Chief Financial Officer | Appointed | 2024-10-10 |
| Michael Edwards | Interim Chief Financial Officer and Principal Accounting Officer | Appointed | 2024-08-23 |
| Michael Dougherty | Chief Financial Officer and Principal Accounting Officer | Resigned | 2024-08-23 |
| Jamie Platt | Director | Appointed | 2024-06-05 |
| Gary Rubin | Director | Appointed | 2024-06-05 |
| Roby Joyce | Director | Appointed | 2024-06-05 |
| Robert Anderson | Director | Appointed | 2024-06-05 |
| Stuart Diamond | Director | Appointed | 2024-06-05 |
| Peter Knight | Director | Appointed | 2024-06-05 |
| Steven Girgenti | Director | Appointed | 2024-06-05 |
| Maria Zannes | Director | Appointed | 2024-06-05 |
| Mohsin Y. Meghji | Board of Directors | Resigned | 2023-12-05 |
| Jamie Platt, Ph.D. | director | Appointed | 2023-12-05 |
| Roby Joyce, M.D. | Laboratory Director and Medical Director of Precision Pathology Laboratory Services, LLC | Appointed | 2023-09-20 |
| Xavier Reveles | Chief Operating Officer | Appointed | 2023-09-20 |
| Roby P. Joyce | Board of Directors | Appointed | 2023-09-20 |
| Gary Rubin | director | Appointed | 2023-06-07 |
| Peter Knight | director | Appointed | 2023-06-07 |
| Stuart Diamond | director | Appointed | 2023-06-07 |
| Mohsin Meghji | director | Appointed | 2023-06-07 |
| Robert Anderson | director | Appointed | 2023-06-07 |
| Steven Girgenti | director | Appointed | 2023-06-07 |